Sensitivity to CPT-11 and platinum derivatives of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1045-1050

  Mukai, Masaya ^a   Sato, Shinkichi ^b   Ninomiya, Hiromi ^b   Wakui, Kanako ^b   Komatsu, Nobukazu ^b   Matsui, Naruaki ^b   Nakamura, Masato ^a   Nakasaki, Hisao ^b   Makuuchi, Hiroyasu ^c  

^a TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^b TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bax; Colorectal cancer; CPT 11; ERCC 1; Isolated tumor cells; Occult neoplastic cells; Platinum agents; Topoisomerase 1 inhibitor

Indexed keywords

BAX PROTEIN, HUMAN; CAMPTOTHECIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; IRINOTECAN; PLATINUM COMPLEX; PROTEIN BAX; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CANCER STAGING; COLORECTAL TUMOR; DRUG ANTAGONISM; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; NEOPLASM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE;

BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; ORGANOPLATINUM COMPOUNDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34548591681     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1045     Document Type: Article

References (38)

1. Mukai M, Ito I, Mukoyama S, Tajima T, Saito Y, Nakasaki H, Sato S and Makuuchi H: Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study. Oncol Rep 10: 927-934, 2003.
2. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes' C colorectal cancer. Oncol Rep 10: 1165-1169, 2003.
3. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes' B colorectal cancer. Oncol Rep 10: 1177-1181, 2003.
4. Mukai M, Sato S, Nishida T, Komatsu N, Shiba K, Nakasaki H and Makuuchi H: Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer. Oncol Rep 10: 1753-1758, 2003.
5. Mukai M, Sato S, Nakasaki H, Saito Y, Nishiumi N, Iwasaki M, Tokuda Y, Ogoshi K, Inoue H and Makuuchi H: Occult neoplastic cells in the lymph node sinuses and recurrence of primary breast, lung, esophageal and gastric cancer. Oncol Rep 11: 81-84, 2004.
6. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of stage II/Dukes' B colorectal cancer without lymph node metastasis. Oncol Rep 12: 1127-1130, 2004.
7. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of stage III/Dukes' C colorectal cancer with lymph node metastasis. Oncol Rep 12: 1301-1304, 2004.
8. Mukai M, Sato S, Tajima T, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Predicting recurrence and metastasis of Dukes' A primary colorectal cancer with or without proper muscle invasion. Oncol Rep 12: 1305-1308, 2004.
9. TNM Classification of Malignant Tumours. 6th edition, John Wiley & Sons, Inc., New York, 2002.
10. Mukai M: Occult neoplastic cells and malignant micro-aggregates in lymph node sinuses: review and hypothesis. Oncol Rep 14: 173-175, 2005.
11. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Tajima T, Nakasaki H and Makuuchi H: Prospective study on the recurrence/metastasis of stage II/III colorectal and gastric cancer associated with occult neoplastic cells in lymph node sinuses: three-year interim results. Oncol Rep 16: 405-410, 2006.
12. Mukai M, Oida Y, Tajima T, Kishima K, Ninomiya H, Sato S, Nakamura M, Nakasaki H and Makuuchi H: Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncol Rep 16: 865-870, 2006.
13. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
14. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller L: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
15. Tournigand C, Achille TAE, Lledo G, Flesh M, Quinaux DM-ME, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and De Gramont A: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004. (Pubitemid 41095086)
16. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Seri MD, Lopez M and Maiello E: Phase III randomized trial of FOLFIRI versus FOLFOX 4 in the treatment of advanced colorectal cancer: a multicenter study of Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23: 4866-4875, 2005. (Pubitemid 46223991)
17. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994. (Pubitemid 24251002)
18. Perego P, Giarosa M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996. (Pubitemid 26043653)
19. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F and Reed E: Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 273: 23419-23425, 1998. (Pubitemid 28417531)
20. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S and Pendyala L: In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmocol 48: 398-406, 2001. (Pubitemid 33027997)
21. Arnould S, Hennebelle I, Canal P, Bugat R and Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39: 112-119, 2003. (Pubitemid 36005433)
22. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1165-1169, 2005.
23. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1171-1176, 2005.
24. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of node-positive stage II/III gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 14: 1505-1510, 2005.
25. Mukai M, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H and Makuuchi H: Recurrence and 5-FU sensitivity of node-negative stage I/II breast, lung, or gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep 15: 815-820, 2006.
26. Nakane PK and Pierce GB: Enzyme-labeled antibodies: preparation and application for localization of antigens. J Histochem Cytochem 14: 929-931, 1966.
27. Nakane PK and Pierce GB: Enzyme-labeled antibody for the light and electron microscopic localization of tissue antigens. J Cell Biol 33: 307-318, 1967.
28. Okabe H, Tsujimoto H and Fukushima M: Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and application to sensitivity-study of 5-fluorouracil. Oncol Rep 4: 685-690, 1997. (Pubitemid 27286971)
29. Kamoshida S, Shiogama K, Matsuoka H, Matsuyama A, Shimomura R, Inada K, Maruta M and Tsutsumi Y: Immunohistochemical demonstration of dihydropyrimidine dehydrogenase in normal and cancerous tissues. Acta Histochem Cytochem 36: 471-479, 2003. (Pubitemid 37433065)
30. Heid CA, Stevens J, Livak KJ and Williams PM: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
31. Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6: 995-1001, 1996. (Pubitemid 26388092)
32. Lord RV, Salong D, Danenberg KD, Peter JH, De Meester SR, Bremner CG, Tsai PI and Danenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142, 2000.
33. Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, Takasaki K, Danenberg KD and Danenberg PV: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in TS gene. Clin Cancer Res 10: 433-439, 2004. (Pubitemid 38173979)
34. Uchida K, Schneider S, Yochim JM, Kuramochi H, Hayashi K, Takasaki K, Yang D, Danenberg KD and Danenberg PV: Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 11: 3363-3368, 2005. (Pubitemid 40627888)
35. Shirota Y, Stoehlmacher J, Brabender J, Xiong Y-P, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz H-J: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001. (Pubitemid 33096777)
36. Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD and Lenz H-J: Molecular determinants of irinotecan efficacy. Int J Cancer 119: 2435-2442, 2006. (Pubitemid 44546969)
37. Feinstein AR, Sosin DM and Wells CK: The Will Rogers phenomenon: stage migration and new techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312: 1604-1608, 1985. (Pubitemid 15062653)
38. Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GL and Bruijn JA: Surgical/pathologic stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13: 19-25, 1995. Organization